UNSPSC 51433912: Cilnidipine

This classification denotes a calcium channel blocker with the molecular formula C27H28N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97T5AZ1JIP, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl ester, (e)-(+-)- but generally known as cilnidipine, which bears US NIH Compound Identifier 5282138. European Medicines Agency schedules Cilnidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06268MIG.

UNSPSC 51433912 Cilnidipine, a Commodity code, encompasses prescription and specialty medications supplied to state and local emergency services, health agencies, and cooperative purchasing alliances. State and local governments are procuring advanced life support medications, generic pharmaceuticals, and over-the-counter products through this code for distribution to fire rescue services, emergency medical systems, and multi-jurisdictional health benefit programs. The issuing bodies include municipal fire departments, state health and human services agencies, and regional cooperative purchasing entities serving multiple states and localities. Procurement activity reflects operational demand from emergency services and strategic cost-management initiatives by state health agencies seeking direct manufacturer relationships or consolidation through cooperative contracts.

Recent opportunities span Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an Invitation for Bid (IFB) No. 26P00188 for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue at an estimated contract value of $40,000.00, with a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with awards effective July 1, 2026, requiring vendors to supply through three authorized wholesalers and maintain cGMP and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission issued Request for Information No. HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling exploratory procurement strategy development for future formal solicitations.